Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (478)	2/28/2005 3:27:06 PM
From: Ian@SI	Read Replies (2) of 946

I'm now listening to the conf call replay from this morning. Generally good stuff going on across the whole pipeline. RE the Stellar 3 stuff: Data still blinded to CTIC. HOWEVER, study of the blinded data shows that there IS a SIGNIFICANT survival benefit to those receiving 4 - 6 doses versus those receiving less. This survival benefit is equally seen in ALL geographic trial areas: North America, Eastern Europe, Western Europe, ... There is no geographic difference. It now seems that the only risk is that for some unknown reason the non Xyotax arm somehow was better able to tolerate treatment.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next